Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial
01:07 EDT 16 Aug 2012 | The Medical News
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on devel..
Original Article: Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial
More From BioPortfolio on "Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
